1
|
Wang H, Wang C, Zhang S, Liu J, Bi X. Impact of anti-VEGF therapy on distinctive retina layers in patients with macular edema secondary to branch retinal vein occlusion. BMC Ophthalmol 2023; 23:235. [PMID: 37231357 DOI: 10.1186/s12886-023-02981-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2022] [Accepted: 05/18/2023] [Indexed: 05/27/2023] Open
Abstract
BACKGROUND To explore the impact of anti-vascular epithelial growth factor (ant-VEGF) on the thickness of each retinal layer in patients with macular edema (ME) secondary to the branch retinal vein occlusion (BRVO). METHODS This retrospective study included patients with ME secondary to monocular BRVO who received anti-VEGF therapy in Ningxia Eye Hospital between January-December 2020. RESULTS Forty-three patients (25 males) were included, with 31 showed > 25% reduction in central retinal thickness (CRT) after anti-VEGF therapy (response group), and the others showed a ≤25% reduction in CRT (no-response group). The response group showed significantly smaller mean changes in the ganglion cell layer (GCL) (after 2 months) and inner plexiform layer (IPL) (after 1, 2, and 3 months) and significantly greater mean changes in the inner nuclear layer (INL) (after 2 and 3 months), outer plexiform layer (OPL) (after 3 months), outer nuclear layer (ONL) (after 2 and 3 months), and CRT (after 1 and 2 months) (all P < 0.05) as compared to the no-response group. The mean change in the thickness of each retinal layer IPL (P = 0.006) between the two groups was significantly different after controlling for a time and with a significant time trend (P < 0.001). Additionally, patients in the response group were more likely to have an improvement in IPL (43.68 ± 6.01 at 1 month and 41.52 ± 5.45 at 2 months vs. 39.9 ± 6.86 at baseline) after anti-VEGF therapy, while those in no response group might show improvement in GCL (45.75 ± 8.24 at 1 month, 40.00 ± 8.92 at 2 months, and 38.83 ± 9.93 at 3 months vs. 49.67 ± 6.83 at baseline). CONCLUSIONS Anti-VEGF therapy might help restore the retinal structure and function in patients with ME secondary to BRVO, and those who have a response after anti-VEGF therapy are more likely to improve IPL, while those having no response might show improvement in GCL.
Collapse
Affiliation(s)
- Hui Wang
- Ophthalmology Center of Changzhi People's Hospital affiliated to Changzhi Medical College, Changzhi City, China
| | - Chanjuan Wang
- Ningxia Eye Hospital, People Hospital of Ningxia Hui Autonomous Region (First Affiliated Hospital of Northwest University for Nationalities), Yinchuan, 750000, China
| | - Shaochi Zhang
- Ningxia Eye Hospital, People Hospital of Ningxia Hui Autonomous Region (First Affiliated Hospital of Northwest University for Nationalities), Yinchuan, 750000, China
| | - Jun Liu
- Ophthalmology Center of Changzhi People's Hospital affiliated to Changzhi Medical College, Changzhi City, China
| | - Xiaojun Bi
- Ningxia Eye Hospital, People Hospital of Ningxia Hui Autonomous Region (First Affiliated Hospital of Northwest University for Nationalities), Yinchuan, 750000, China.
| |
Collapse
|
2
|
Itou J, Furushima K, Haruta M, Kato N, Arai R, Mori K, Ishikawa K, Yoshida S. Reduced Size of Telangiectatic Capillaries After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents in Diabetic Macular Edema. Clin Ophthalmol 2023; 17:239-245. [PMID: 36698851 PMCID: PMC9869900 DOI: 10.2147/opth.s393360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Accepted: 12/06/2022] [Indexed: 01/19/2023] Open
Abstract
Purpose Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents reduces microaneurysms in patients with diabetic macular edema (DME). However, residual anti-VEGF-resistant telangiectatic capillaries (TelCaps) have been reported. In this study, we investigated changes in the size of TelCaps after intravitreal injection of anti-VEGF agents in DME. Patients and Methods Indocyanine green angiography (IA) and optical coherence tomography were performed before and 3 months after the intravitreal injection of anti-VEGF agents (pro re nata regimen after three monthly loading doses) in 12 eyes of 12 patients (7 males and 5 females, mean age 65.2 ± 8.8 years) with DME. The number and size of TelCaps within a 6-mm diameter macular region of the edema were measured using optical coherence tomography B-scan images overlaid on IA images. Results There were significant reductions in the number and size of TelCaps between the baseline and 3 months after anti-VEGF agent administration (P < 0.05 and P < 0.0001, respectively). The maximum corrected visual acuity (logMAR visual acuity) and the central macular thickness after anti-VEGF therapy were significantly improved (P < 0.01 and P < 0.02, respectively). The TelCaps remaining after loading three consecutive anti-VEGF agents had a significantly larger mean size at baseline than the TelCaps that resolved after the treatment (P < 0.03). Conclusion Our study demonstrated that intravitreal injection of anti-VEGF agents could reduce TelCap size in patients with DME. We propose that larger-sized TelCaps detected by IA might be useful predictors of refractory DME, which could thus be principal targets of laser photocoagulation.
Collapse
Affiliation(s)
- Junichi Itou
- Department of Ophthalmology, Kurume University School of Medicine, Kurume, Japan
| | - Kei Furushima
- Department of Ophthalmology, Kurume University School of Medicine, Kurume, Japan
| | - Masatoshi Haruta
- Department of Ophthalmology, Kurume University School of Medicine, Kurume, Japan
| | - Nobuhiro Kato
- Department of Ophthalmology, Kurume University School of Medicine, Kurume, Japan
| | - Rikki Arai
- Department of Ophthalmology, Kurume University School of Medicine, Kurume, Japan
| | - Kenichiro Mori
- Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Keijiro Ishikawa
- Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Shigeo Yoshida
- Department of Ophthalmology, Kurume University School of Medicine, Kurume, Japan,Correspondence: Shigeo Yoshida, Department of Ophthalmology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan, Tel +81-942-317574, Fax +81-942-370324, Email
| |
Collapse
|
3
|
Changes in metamorphopsia following intravitreal aflibercept injection for diabetic macular edema. Sci Rep 2022; 12:17356. [PMID: 36253499 PMCID: PMC9574178 DOI: 10.1038/s41598-022-22401-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Accepted: 10/14/2022] [Indexed: 01/10/2023] Open
Abstract
The aim of the present study was to investigate changes in metamorphopsia in patients with diabetic macular edema (DME) following intravitreal aflibercept injection (IVA) with the treat and extend (TAE) regimen for a year. We performed a post hoc analysis of a multicenter, open-label, single-arm, prospective study. The study included 20 patients with DME. All eyes received 3 monthly loading injections of 2 mg aflibercept, followed by a TAE regimen. Every visit, the severity of metamorphopsia and the best-corrected visual acuity (BCVA) were evaluated, and optical coherence tomography (OCT) images were obtained. The severity of metamorphopsia was measured using M-CHARTS. The metamorphopsia scores before treatment and at 1, 2, 3, 6 and 12 months following treatment were 0.25 ± 0.23, 0.21 ± 0.15, 0.19 ± 0.23, 0.14 ± 0.16, 0.17 ± 0.20 and 0.10 ± 0.17, respectively, with significant improvement from before treatment to 3 and 12 months following treatment (p < 0.05 and p < 0.005, respectively). At the time of macular edema resolution, the presence of an epiretinal membrane (ERM) was associated with the metamorphopsia score (p < 0.05). In conclusion, the metamorphopsia score in patients with DME improved following IVA with the TAE regimen for one year. The presence of ERM was associated with the metamorphopsia score.
Collapse
|
4
|
Wang Y, Wang S, Wang S, Ding M, Zhang M, Tang J, Deng A. Chorioretinal venous anastomosis for non-ischemic retinal vein occlusion. FRONTIERS IN OPHTHALMOLOGY 2022; 2:869843. [PMID: 38983556 PMCID: PMC11182135 DOI: 10.3389/fopht.2022.869843] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/05/2022] [Accepted: 07/04/2022] [Indexed: 07/11/2024]
Abstract
Retinal vein occlusion (RVO) refers to the occlusion of the central retinal vein or primary and secondary branches caused by multiple factors. Clinical treatments for it include intravitreal or systemic vasodilator application, local usage of steroids and NSAID (non-steroidal anti-inflammatory drugs), thrombolysis, hemodilution, retinal laser photocoagulation, vitrectomy with vascular sheath incision, chorioretinal venous anastomosis (CRVA), and so on. At present, most treatments are aimed at RVO complications, while chorioretinal vein anastomosis can fundamentally reflux retinal vein blood through the choroid by venous vascular remodeling. Reports on the treatment of retinal vein occlusion by chorioretinal anastomosis are numerous in various countries. As a treatment means, CRVA can drain the venous blood, skipping the thrombosis spot, thus partially relieving anatomical vascular occlusion to achieve a therapeutic purpose. In this study, CRVA is evaluated from the aspects of indications, implementation process, postoperative effect evaluation, complications, and combination with anti-VEGF treatment. Based on the development of laser technology and vitrectomy, we hope to further review this treatment and provide a new reference for the clinical treatment of RVO.
Collapse
Affiliation(s)
- Yucheng Wang
- Eye Center of Affiliated Hospital of Weifang Medical University, Weifang, China
- Weifang Medical University, Weifang, China
| | - Shaolong Wang
- Eye Center of Affiliated Hospital of Weifang Medical University, Weifang, China
- Weifang Medical University, Weifang, China
| | - Shiwu Wang
- Eye Center of Affiliated Hospital of Weifang Medical University, Weifang, China
- Weifang Medical University, Weifang, China
| | - Min Ding
- Eye Center of Affiliated Hospital of Weifang Medical University, Weifang, China
| | - Min Zhang
- Eye Center of Affiliated Hospital of Weifang Medical University, Weifang, China
- Weifang Medical University, Weifang, China
| | - Jiannan Tang
- Eye Center of Affiliated Hospital of Weifang Medical University, Weifang, China
- Weifang Medical University, Weifang, China
| | - Aijun Deng
- Eye Center of Affiliated Hospital of Weifang Medical University, Weifang, China
- Weifang Medical University, Weifang, China
| |
Collapse
|
5
|
Nanji K, Khan M, Khalid MF, Xie JS, Sarohia GS, Phillips M, Thabane L, Garg SJ, Kaiser P, Sivaprasad S, Wykoff CC, Chaudhary V. Treat-and-extend regimens of anti-vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta-analysis. Acta Ophthalmol 2021; 100:e1199-e1208. [PMID: 34845830 DOI: 10.1111/aos.15068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Revised: 10/12/2021] [Accepted: 11/19/2021] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To investigate treat-and-extend (T&E) regimens of anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of macular oedema secondary to retinal vein occlusions (RVOs). METHODS Ovid MEDLINE, Ovid EMBASE and CENTRAL were searched on 25 February 2021. Randomized controlled trials, cohort studies, case-control studies and case series were included. The primary outcome was the change in Early Treatment Diabetic Retinopathy Score (ETDRS) letters from baseline. Conversions from Snellen to ETDRS letters were performed utilizing a published protocol. Secondary outcomes included improvement in retinal thickness from baseline, number of anti-VEGF injections and frequency of adverse events. Outcomes were examined at 12 and 24 months. Certainty of evidence was assessed utilizing GRADE (Grading of Recommendations Assessments, Development and Evaluations) guidelines. RESULTS Seven hundred eighty-six eyes from 16 studies were included. Meta-analysis demonstrated a mean improvement of 15.7 (95% CI: 13.3-18.0) ETDRS letters at 12 months. Central retinal thickness improved 269.7 μm (95% CI: 233.64-305.90) at 12 months. Injections were performed 8.1 (95% CI: 7.4-8.7) and 13.1 (95% CI: 9.4-16.8) times at 12 and 24 months respectively. Adverse events were infrequent across all studies. Grading of Recommendations Assessments, Development and Evaluations (GRADE) certainty of evidence was very low across all outcomes. CONCLUSIONS The results support the viability of T&E regimens for the treatment of macular oedema secondary to RVOs.
Collapse
Affiliation(s)
- Keean Nanji
- Department of Surgery Division of Ophthalmology McMaster University Hamilton Ontario Canada
| | - Mohammad Khan
- Department of Surgery Division of Ophthalmology McMaster University Hamilton Ontario Canada
| | - Muhammad F. Khalid
- Department of Surgery Division of Ophthalmology McMaster University Hamilton Ontario Canada
| | - Jim S. Xie
- Department of Surgery Division of Ophthalmology McMaster University Hamilton Ontario Canada
| | - Gurkaran S. Sarohia
- Department of Ophthalmology and Visual Sciences 2319 Active Treatment Centre University of Alberta Edmonton Alberta Canada
| | - Mark Phillips
- Department of Health Research Methods, Evidence and Impact McMaster University Hamilton Ontario Canada
| | - Lehana Thabane
- Department of Health Research Methods, Evidence and Impact McMaster University Hamilton Ontario Canada
- St. Joseph’s Healthcare‐Hamilton Biostatistics Unit Hamilton Ontario Canada
| | - Sunir J. Garg
- The Retina Service of Wills Eye Hospital MidAtlantic Retina Philadelphia PA USA
| | - Peter Kaiser
- Cleveland Clinic Cole Eye Institute Cleveland Ohio USA
| | - Sobha Sivaprasad
- Moorfields Eye Hospital NIHR Moorfields Biomedical Research Centre London UK
| | - Charles C. Wykoff
- Retina Consultants of Houston, Texas Blanton Eye Institute Houston Methodist Hospital and Weill Cornell Medical College Houston Texas USA
| | - Varun Chaudhary
- Department of Surgery Division of Ophthalmology McMaster University Hamilton Ontario Canada
- Department of Health Research Methods, Evidence and Impact McMaster University Hamilton Ontario Canada
| |
Collapse
|